Ibrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myeloma

Multiple Myeloma (MM) is a haematologic malignancy characterized by the accumulation of clonal plasma cells in the bone marrow. Over the last 10–15 y the introduction of the proteasome-inhibitor bortezomib has improved MM prognosis, however relapse due to bortezomib-resistance is inevitable and the...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Cell Cycle
Huvudupphovsmän: Murray, Megan Y, Zaitseva, Lyubov, Auger, Martin J, Craig, Jenny IO, MacEwan, David J, Rushworth, Stuart A, Bowles, Kristian M
Materialtyp: Artigo
Språk:Inglês
Publicerad: Taylor & Francis 2015
Ämnen:
Report
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4613153/
https://ncbi.nlm.nih.gov/pubmed/25565020
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384101.2014.998067
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk